UpdatesPress Release
Hikal's Q1FY27 revenue hit ₹403 Cr (+6.2% YoY), EBITDA ₹37 Cr (+47.4%). Pharma saw recovery (+15.2%) with new cGMP plant.
Hikal LimitedHIKAL · Filed with the exchange
Crop Protection's CDMO was soft, but Own Products grew.
Personal Care business commercialized.
US FDA remediation is ongoing.
No comments yet. Be the first.